Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BMB-101 in healthy volunteers
NCT05397041Phase 1Completed
- Sponsor
- Bright Minds Biosciences Inc.
- Start
- Jun 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BMB-101 in Dravet syndrome, Lennox-Gastaut syndrome (LGS), absence epilepsy and 1 more (5 arms), sponsored by Bright Minds Biosciences Inc. Primary endpoints: Number of Treatment-emergent Adverse Events and Change in Columbia-Suicide Severity Rating Scale Response. Started Jun 2022; status: completed.
02
Drugs
BMB-101
03
Conditions
Dravet syndromeLennox-Gastaut syndrome (LGS)absence epilepsyepilepsy
Beyond the preview
Go deeper on NCT05397041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05397041.